Supplementary Figures 1-2, Table 1 from FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations &lt;i&gt;In vitro&lt;/i&gt;